Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Pacific Edge Limited ( (PFGTF) ) has issued an update.
Pacific Edge Limited announced that it will release its full-year financial results for FY25 on May 30, 2025. The announcement will be followed by an investor and analyst conference call. The release of these results is significant for stakeholders as it provides insights into the company’s financial health and operational performance, potentially impacting its market positioning and future strategies.
More about Pacific Edge Limited
Pacific Edge Limited is a global leader in cancer diagnostics, specializing in bladder cancer diagnostic and prognostic tests. Based in Dunedin, New Zealand, the company offers its Cxbladder suite of non-invasive genomic urine tests, which are designed for the risk stratification of urothelial cancer. These tests are available in the US, Australasia, Israel, and other international markets, supported by extensive research and numerous peer-reviewed publications.
YTD Price Performance: -40.74%
Average Trading Volume: 73,698
Technical Sentiment Signal: Sell
Current Market Cap: A$65.81M
See more insights into PFGTF stock on TipRanks’ Stock Analysis page.